Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07780890

A Study to Assess Brillouin Hydration Mapping for the Evaluation of Ocular Tissues and Diseases

The overall goal of this study is to develop Brillouin microscope as a novel tool for measuring biomechanical and hydration properties of human tissues in vivo.

Recruiting

Interested in participating?

Request Info

Key information

Age range

20 year–79 year

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

Our long-term goal is to establish a direct, accurate, and clinically viable method for measuring corneal hydration, enabling earlier detection, more precise diagnosis, and improved management of corneal diseases and postoperative complications. The objective of this study is to develop and validate Brillouin based hydration mapping as a diagnostic tool to quantify water content in the cornea across healthy individuals and patients with diverse ocular conditions. Our central hypothesis is that spatially resolved Brillouin frequency shifts can reveal disease-specific hydration profiles that are not detectable through conventional thickness-based methods. This hypothesis is based on recent evidence from our group demonstrating that Brillouin microscopy is sensitive to hydration. The rationale for this research is that Brillouin-based hydration maps will offer an unprecedented, morphology-independent metric of corneal fluid balance, which could improve clinical decision-making in a range of pathologies.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy volunteers with normal eyes
  • Visual acuity between +2 to -6 diopters

Exclusion criteria

  • History of refractive or cataract surgery
  • History of ocular disease
  • Active non-ophthalmic systemic disease

Treatment and study plan

Primary outcomes

  1. Number of subjects to successfully complete Brillouin measurement without serious unanticipated adverse events related to application of the device.

    Time frame: Through completion of the single study visit, approximately 1-2 hours

    Number and percentage of enrolled subjects who complete the single Brillouin imaging session without experiencing a serious unanticipated adverse event related to the investigational Brillouin Ocular Scanner, as determined by study staff monitoring during and immediately following the imaging procedure.

Study contacts

Contact information is provided by the study sponsor or research team.

Seok-Hyun Yun, PhD

CONTACT

[email protected]

6177688704

Soyeon (Selina) Ahn, PhD

CONTACT

[email protected]

3396009736

Sponsors and collaborators

Lead sponsor

Massachusetts General Hospital

Other

Collaborators

  • Massachusetts Eye and Ear Infirmary
  • National Eye Institute (NEI)

Registry information

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Aug 24, 2026
Registry last updated
Aug 25, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.